Is This Healthcare Stock a Millionaire Maker? [Globe and Mail, The (Toronto, Canada)]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Globe and Mail, The
Although its long-term outlook is uncertain, Axsome Therapeutics is worth a second look. Axsome Therapeutics (NASDAQ: AXSM) , a midcap biotech, went public in 2015. Since then, the stock has delivered market-beating returns thanks to significant clinical and regulatory progress, as well as a portfolio of now-approved drugs that generate solid sales. Axsome Therapeutics might only be getting started. The company still has a deep pipeline and plenty of catalysts ahead. But does it have what it takes to turn average investors into millionaires? Lots of moving parts If you had invested $50,000 into Axsome Therapeutics following its IPO, you would be sitting on close to $1 million today, given its compound annual growth rate of 33.32% over this period. Can the biotech pull off a similar performance through the next decade? That's unlikely, as it would give the company a market cap of about $157 billion, making it one of the largest drugmakers in the world. It's not impossible, to be
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (AXSM) had its price target raised by UBS Group AG from $251.00 to $259.00. They now have a "buy" rating on the stock.MarketBeat
- Is This Healthcare Stock a Millionaire Maker? [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4GlobeNewswire
- Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric ConditionsGlobeNewswire
- Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 4/1/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 2/27/26 - Form 4
- AXSM's page on the SEC website